PDF herunterladen
Semin Respir Crit Care Med 2005; 26(3): 342-352
DOI: 10.1055/s-2005-871993
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Bronchioloalveolar carcinoma: A Review of the Epidemiology, Pathology, and Treatment

David M. Jackman1 , 2 , Lucian R. Chirieac3 , Pasi A. Jänne1 , 2
  • 1Dana Farber Cancer Institute, Boston, Massachusetts
  • 2Departments of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
29. Juni 2005 (online)

    Lizenzen und Reprints

ABSTRACT

Bronchioloalveolar carcinoma (BAC) is an important subtype of pulmonary adenocarcinoma. It has received increasing attention in recent years, due to its increasing incidence and its rate of sensitivity to epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs). This article reviews the epidemiology, risk factors, pathology, clinical presentation, and treatment of this disease. Special focus is paid to the emerging role of oral EGFR-TKIs in Bronchioloalveolar cell carcinoma.

KEYWORDS

Adenocarcinoma - Bronchioloalveolar - carcinoma - non-small cell lung - receptor - epidermal growth factor - smoking

REFERENCES

  • 1 Liebow A A. Bronchiolo-alveolar carcinoma.  Adv Intern Med. 1960;  10 329-358
    PubMedGoogle Scholar
  • 2 Travis W D. World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart Lyon Oxford; IARC Press, Oxford University Press (distributor) 2004
    Google Scholar
  • 3 Jemal A, Murray T, Ward E et al.. Cancer statistics, 2005.  CA Cancer J Clin. 2005;  55 10-30
    CrossrefPubMedGoogle Scholar
  • 4 Brambilla E, Travis W D, Colby T V, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours.  Eur Respir J. 2001;  18 1059-1068
    CrossrefPubMedGoogle Scholar
  • 5 Barsky S H, Cameron R, Osann K E, Tomita D, Holmes E C. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features.  Cancer. 1994;  73 1163-1170
    CrossrefPubMedGoogle Scholar
  • 6 Auerbach O, Garfinkel L. The changing pattern of lung carcinoma.  Cancer. 1991;  68 1973-1977
    CrossrefPubMedGoogle Scholar
  • 7 Hsu C P, Chen C Y, Hsu N Y. Bronchioloalveolar carcinoma.  J Thorac Cardiovasc Surg. 1995;  110 374-381
    PubMedGoogle Scholar
  • 8 Harpole D H, Bigelow C, Young Jr W G, Wolfe W G, Sabiston Jr D C. Alveolar cell carcinoma of the lung: a retrospective analysis of 205 patients.  Ann Thorac Surg. 1988;  46 502-507
    PubMedGoogle Scholar
  • 9 Travis W D, Travis L B, Devesa S S. Lung cancer.  Cancer. 1995;  75(1 Suppl) 191-202
    CrossrefPubMedGoogle Scholar
  • 10 Read W L, Page N C, Tierney R M, Piccirillo J F, Govindan R. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database.  Lung Cancer. 2004;  45 137-142
    CrossrefPubMedGoogle Scholar
  • 11 Falk R T, Pickle L W, Fontham E T et al.. Epidemiology of bronchioloalveolar carcinoma.  Cancer Epidemiol Biomarkers Prev. 1992;  1 339-344
    PubMedGoogle Scholar
  • 12 Rolen K A, Fulton J P, Tamura D J, Strauss G M. Bronchioloalveolar carcinoma (BAC) of the lung is related to cigarette smoking: A case-control study from Rhode Island (RI) [abstract 2711].  Proc Am Soc Clin Oncol. 2003;  22 674
    PubMedGoogle Scholar
  • 13 Morabia A, Wynder E L. Relation of bronchioloalveolar carcinoma to tobacco.  BMJ. 1992;  304 541-543
    PubMedGoogle Scholar
  • 14 Morton W E, Treyve E L. Histologic differences in occupational risks of lung cancer incidence.  Am J Ind Med. 1982;  3 441-457
    PubMedGoogle Scholar
  • 15 Rothschild H, Mulvey J J. An increased risk for lung cancer mortality associated with sugarcane farming.  J Natl Cancer Inst. 1982;  68 755-760
    PubMedGoogle Scholar
  • 16 Palmarini M, Fan H. Retrovirus-induced ovine pulmonary adenocarcinoma: an animal model for lung cancer.  J Natl Cancer Inst. 2001;  93 1603-1614
    PubMedGoogle Scholar
  • 17 Sharp J M. Sheep pulmonary adenomatosis: a contagious tumour and its cause.  Cancer Surv. 1987;  6 73-83
    PubMedGoogle Scholar
  • 18 Sigurdsson B. Adenomatosis of sheep's lungs: experimental transmission.  Arch Gesamte Virusforsch. 1958;  8 51-58
    PubMedGoogle Scholar
  • 19 Palmarini M, Sharp J M, de las Heras M, Fan H. Jaagsiekte sheep retrovirus is necessary and sufficient to induce a contagious lung cancer in sheep.  J Virol. 1999;  73 6964-6972
    PubMedGoogle Scholar
  • 20 Garcia-Goti M, Gonzalez L, Cousens C et al.. Sheep pulmonary adenomatosis: characterization of two pathological forms associated with jaagsiekte retrovirus.  J Comp Pathol. 2000;  122 55-65
    CrossrefPubMedGoogle Scholar
  • 21 De las Heras M, Barsky S H, Hasleton P et al.. Evidence for a protein related immunologically to the jaagsiekte sheep retrovirus in some human lung tumours.  Eur Respir J. 2000;  16 330-332
    CrossrefPubMedGoogle Scholar
  • 22 Travis W, Colby T, Corrin B et al.. The World Health Organization Histological Typing of Lung and Pleural Tumors. 3rd ed. Berlin; Springer Verlag 1999
    Google Scholar
  • 23 Clayton F. Bronchioloalveolar carcinomas: cell types, patterns of growth, and prognostic correlates.  Cancer. 1986;  57 1555-1564
    PubMedGoogle Scholar
  • 24 Daly R C, Trastek V F, Pairolero P C et al.. Bronchioloalveolar carcinoma: factors affecting survival.  Ann Thorac Surg. 1991;  51 368-376 discussion 376-377
    PubMedGoogle Scholar
  • 25 Greco R J, Steiner R M, Goldman S, Cotler H, Patchefsky A, Cohn H E. Bronchioloalveolar cell carcinoma of the lung.  Ann Thorac Surg. 1986;  41 652-656
    PubMedGoogle Scholar
  • 26 Manning Jr J T, Spjut H J, Tschen J A. Bronchioloalveolar carcinoma: the significance of two histopathologic types.  Cancer. 1984;  54 525-534
    PubMedGoogle Scholar
  • 27 Matthews M J, Mackay B, Lukeman J. The pathology of non-small cell carcinoma of the lung.  Semin Oncol. 1983;  10 34-55
    PubMedGoogle Scholar
  • 28 Travis W D. Pathology of lung cancer.  Clin Chest Med. 2002;  23 65-81
    CrossrefPubMedGoogle Scholar
  • 29 Singh G, Katyal S L. Clara Cell Proteins.  Ann N Y Acad Sci. 2000;  923 43-58
    PubMedGoogle Scholar
  • 30 Singh G, Katyal S L, Torikata C. Carcinoma of type II pneumocytes: PAS staining as a screening test for nuclear inclusions of surfactant specific apoprotein.  Cancer. 1982;  50 946-948
    PubMedGoogle Scholar
  • 31 Sidhu G S, Wieczorek R, Cassai N D, Zhu C C. The concept of bronchioloalveolar cell adenocarcinoma: redefinition, a critique of the 1999 WHO classification, and an ultrastructural analysis of 155 cases.  Int J Surg Pathol. 2003;  11 89-99
    PubMedGoogle Scholar
  • 32 Bennett D E, Sasser W F. Bronchiolar carcinoma: a valid clinicopathologic entity? A study of 30 cases.  Cancer. 1969;  24 876-887
    PubMedGoogle Scholar
  • 33 Greenberg S D, Smith M N, Spjut H J. Bronchiolo-alveolar carcinoma: cell of origin.  Am J Clin Pathol. 1975;  63 153-167
    PubMedGoogle Scholar
  • 34 Copin M C, Buisine M P, Leteurtre E et al.. Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas.  Hum Pathol. 2001;  32 274-281
    CrossrefPubMedGoogle Scholar
  • 35 Lau S K, Luthringer D J, Eisen R N. Thyroid transcription factor-1: a review.  Appl Immunohistochem Mol Morphol. 2002;  10 97-102
    CrossrefPubMedGoogle Scholar
  • 36 Shah R N, Badve S, Papreddy K, Schindler S, Laskin W B, Yeldandi A V. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma.  Hum Pathol. 2002;  33 915-920
    CrossrefPubMedGoogle Scholar
  • 37 Saad R S, Cho P, Silverman J F, Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma.  Am J Clin Pathol. 2004;  122 421-427
    CrossrefPubMedGoogle Scholar
  • 38 Saad R S, Liu Y L, Han H, Landreneau R J, Silverman J F. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.  Hum Pathol. 2004;  35 3-7
    CrossrefPubMedGoogle Scholar
  • 39 Simsir A, Wei X J, Yee H, Moreira A, Cangiarella J. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens.  Am J Clin Pathol. 2004;  121 350-357
    CrossrefPubMedGoogle Scholar
  • 40 Lau S K, Desrochers M J, Luthringer D J. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases.  Mod Pathol. 2002;  15 538-542
    CrossrefPubMedGoogle Scholar
  • 41 Goldstein N S, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies.  Am J Clin Pathol. 2001;  116 319-325
    CrossrefPubMedGoogle Scholar
  • 42 Johansson L. Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping.  Ann Diagn Pathol. 2004;  8 259-267
    PubMedGoogle Scholar
  • 43 Jerome Marson V, Mazieres J, Groussard O et al.. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade.  Histopathology. 2004;  45 125-134
    CrossrefPubMedGoogle Scholar
  • 44 Awaya H, Takeshima Y, Yamasaki M, Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung.  Am J Clin Pathol. 2004;  121 644-653
    CrossrefPubMedGoogle Scholar
  • 45 Westra W H. Early glandular neoplasia of the lung.  Respir Res. 2000;  1 163-169
    CrossrefPubMedGoogle Scholar
  • 46 Lee K S, Kim Y, Han J, Ko E J, Park C K, Primack S L. Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings.  Radiographics. 1997;  17 1345-1357
    PubMedGoogle Scholar
  • 47 Breathnach O S, Ishibe N, Williams J, Linnoila R I, Caporaso N, Johnson B E. Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung.  Cancer. 1999;  86 1165-1173
    CrossrefPubMedGoogle Scholar
  • 48 Hiratsuka T, Mukae H, Ihiboshi H et al.. Severe bronchorrhea accompanying alveolar cell carcinoma: treatment with clarithromycin and inhaled beclomethasone.  Nihon Kokyuki Gakkai Zasshi. 1998;  36 482-487
    PubMedGoogle Scholar
  • 49 Hidaka N, Nagao K. Bronchioloalveolar carcinoma accompanied by severe bronchorrhea.  Chest. 1996;  110 281-282
    PubMedGoogle Scholar
  • 50 Dwek J H, Charytan C, Stachura I, Kaganowicz A. Salt-wasting bronchorrhea and its mechanisms.  Arch Intern Med. 1977;  137 791-794
    CrossrefPubMedGoogle Scholar
  • 51 Homma S, Kawabata M, Kishi K et al.. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma.  Chest. 1999;  115 1465-1468
    CrossrefPubMedGoogle Scholar
  • 52 Marom Z M, Goswami S K. Respiratory mucus hypersecretion (bronchorrhea): a case discussion-possible mechanisms(s) and treatment.  J Allergy Clin Immunol. 1991;  87 1050-1055
    PubMedGoogle Scholar
  • 53 Chang G C, Yang T Y, Wang N S, Huang C M, Chiang C D. Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.  J Formos Med Assoc. 2003;  102 407-411
    PubMedGoogle Scholar
  • 54 Milton D T, Kris M G, Gomez J E, Feinstein M B. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).  Support Care Cancer. 2005;  13 70-72
    PubMedGoogle Scholar
  • 55 Takao M, Inoue K, Watanabe F et al.. Successful treatment of persistent bronchorrhea by gefitinib in a case with recurrent bronchioloalveolar carcinoma: a case report.  World J Surg Oncol. 2003;  1 8
    PubMedGoogle Scholar
  • 56 Yano S, Kanematsu T, Miki T et al.. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (“Iressa”).  Cancer Sci. 2003;  94 453-458
    PubMedGoogle Scholar
  • 57 Chetty K G, Dick C, McGovern J, Conroy R M, Mahutte C K. Refractory hypoxemia due to intrapulmonary shunting associated with bronchioloalveolar carcinoma.  Chest. 1997;  111 1120-1121
    PubMedGoogle Scholar
  • 58 Barlesi F, Doddoli C, Thomas P, Kleisbauer J P, Giudicelli R, Fuentes P. Bilateral bronchioloalveolar lung carcinoma: is there a place for palliative pneumonectomy?.  Eur J Cardiothorac Surg. 2001;  20 1113-1116
    CrossrefPubMedGoogle Scholar
  • 59 Trigaux J P, Gevenois P A, Goncette L, Gouat F, Schumaker A, Weynants P. Bronchioloalveolar carcinoma: computed tomography findings.  Eur Respir J. 1996;  9 11-16
    CrossrefPubMedGoogle Scholar
  • 60 Regnard J F, Santelmo N, Romdhani N et al.. Bronchioloalveolar lung carcinoma: results of surgical treatment and prognostic factors.  Chest. 1998;  114 45-50
    CrossrefPubMedGoogle Scholar
  • 61 Breathnach O S, Kwiatkowski D J, Finkelstein D M et al.. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease.  J Thorac Cardiovasc Surg. 2001;  121 42-47
    CrossrefPubMedGoogle Scholar
  • 62 Ebright M I, Zakowski M F, Martin J et al.. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.  Ann Thorac Surg. 2002;  74 1640-1646 discussion 1646-1647
    CrossrefPubMedGoogle Scholar
  • 63 Noguchi M, Morikawa A, Kawasaki M et al.. Small adenocarcinoma of the lung. Histologic characteristics and prognosis.  Cancer. 1995;  75 2844-2852
    CrossrefPubMedGoogle Scholar
  • 64 Rena O, Papalia E, Ruffini E et al.. Stage I pure bronchioloalveolar carcinoma: recurrences, survival and comparison with adenocarcinoma of the lung.  Eur J Cardiothorac Surg. 2003;  23 409-414
    CrossrefPubMedGoogle Scholar
  • 65 Yamato Y, Tsuchida M, Watanabe T et al.. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung.  Ann Thorac Surg. 2001;  71 971-974
    CrossrefPubMedGoogle Scholar
  • 66 Watanabe S, Watanabe T, Arai K, Kasai T, Haratake J, Urayama H. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography.  Ann Thorac Surg. 2002;  73 1071-1075
    CrossrefPubMedGoogle Scholar
  • 67 Feldman E R, Eagan R T, Schaid D J. Metastatic bronchioloalveolar carcinoma and metastatic adenocarcinoma of the lung: comparison of clinical manifestations, chemotherapeutic responses, and prognosis.  Mayo Clin Proc. 1992;  67 27-32
    PubMedGoogle Scholar
  • 68 Sorensen J B, Hirsch F R, Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization: an analysis of 259 consecutive patients with advanced disease.  Cancer. 1988;  62 361-367
    PubMedGoogle Scholar
  • 69 Miller V A, Kris M G, Shah N et al.. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bonchioalveolar cell carcinoma (BAC): preliminary results of a phase II trial [abstract 2491].  Proc Am Soc Clin Oncol. 2003;  22 619
    PubMedGoogle Scholar
  • 70 Janne P A, Ostler P A, Lucca J et al.. ZD1839 (“Iressa”) shows antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol.  Proc Am Soc Clin Oncol. 2002;  21 319
    PubMedGoogle Scholar
  • 71 Fukuoka M, Yano S, Giaccone G et al.. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). [corrected].  J Clin Oncol. 2003;  21 2237-2246
    CrossrefPubMedGoogle Scholar
  • 72 Miller V A, Kris M G, Shah N et al.. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.  J Clin Oncol. 2004;  22 1103-1109
    CrossrefPubMedGoogle Scholar
  • 73 Kris M G, Natale R B, Herbst R S et al.. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.  JAMA. 2003;  290 2149-2158
    CrossrefPubMedGoogle Scholar
  • 74 Paez J G, Janne P A, Lee J C et al.. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.  Science. 2004;  304 1497-1500
    CrossrefPubMedGoogle Scholar
  • 75 Lynch T J, Bell D W, Sordella R et al.. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2004;  350 2129-2139
    CrossrefPubMedGoogle Scholar
  • 76 Natale R B, Shak S, Aronson N et al.. Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: predicting response to gefitinib, an EGFR kinase inhibitor [abstract 763].  Proc Am Soc Clin Oncol. 2003;  22 190
    PubMedGoogle Scholar
  • 77 Marchetti A, Martella C, Felicioni L et al.. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.  J Clin Oncol. 2005;  23 857-865
    CrossrefPubMedGoogle Scholar
  • 78 Shigematsu H, Lin L, Takahashi T et al.. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.  J Natl Cancer Inst. 2005;  97 339-346
    CrossrefPubMedGoogle Scholar
  • 79 Kris M G, Sandler A, Miller V A et al.. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC) [abstract 7062].  Proc Am Soc Clin Oncol. 2004;  22 14S
    PubMedGoogle Scholar
  • 80 West H, Franklin W A, Gumerlock P H et al.. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126 [abstract 7014].  Proc Am Soc Clin Oncol. 2004;  22 14S
    PubMedGoogle Scholar
  • 81 Jackman D J, Lucca J, Fidias P et al.. Phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma [abstract 7148].  Proc Am Soc Clin Oncol. 2005; 
    PubMedGoogle Scholar

Pasi JanneM.D. 

Department of Medicine, Dana Farber Cancer Institute

DF-D1234, 44 Binney St., Boston, MA 02115

eMail: Pjanne@Partners.org

      >